Table 1.

The demographic information of the study population

Clinical Indicators	Primary cohort (n = 319)	Validation cohort (n = 96)	P
Age	49(43,56)	50(44,56)	0.286
BMI	22.89(21.08,24.75)	23.28(20.87,25.03)	0.638
Subtypes			0.361
SCC	238(74.6%)	76(79.2%)
AC	81(25.4%)	20(20.8%)
Menopausal Status			0.823
No	162(50.8%)	50(52.0%)
Yes	157(49.2%)	46(48.0%)
Clinical Symptoms			0.444
Asymptomatic or Other	69(21.7%)	25(26.0%)
Contact Bleeding	166(52.0%)	43(44.8%)
Irregular Vaginal Bleeding	84(26.3%)	28(29.2%)
Smoking History			0.147
No	307(96.2%)	89(92.7%)
Yes	12(3.8%)	7(7.3%)
Gravidity	3(2,4)	3(2,5)	0.545
Parity	2(1,2)	2(1,2)	0.469
RBC	4.06(3.85,4.36)	4.15(3.92,4.38)	0.245
WBC	5.46(4.57,6.59)	5.05(4.35,6.09)	0.034*
PLT	209(174.00,242.00)	209(170.00,242.00)	0.566
Neutrophil Percentage	58.0(52.9,63.5)	54.9(50.9,60.1)	0.005*
Lymphocyte Percentage	31.1(26.3,36.3)	33.9(29.3,39.1)	0.004*
SCCAg	1.3(0.9,2.5)	2.0(1.0,2.9)	0.003*
CA125	14.6(11.0,22.8)	14.2(10.4,19.2)	0.369
CA19-9	10.9(7.4,17.2)	8.7(6.1,12.9)	0.005*
CYFRA 21–1	2.4(1.7,3.2)	2.4(1.9,3.4)	0.158
CEA	1.8(1.1,2.9)	1.9(1.3,3.2)	0.789
HPV Subtypes			0.253
Low Risk	233(73.1%)	78(81.2%)
Medium Risk	16(5.0%)	4(4.2%)
High Risk	70(21.9%)	14(14.6%)

^*A p value of < 0.05 was considered to indicate significant difference